Citius Pharmaceuticals Inc. (NASDAQ:CTXR) shares jumped 22.12% in after-hours trading to $1.27 on Tuesday, following the company’s fiscal year 2025 business update and the commercial launch of its flagship oncology therapy.Check out the current price of CTXR stock here. LYMPHIR Launch Marks First New CTCL Therapy Since 2018The New Jersey-based biopharmaceutical company announced on Tuesday that LYMPHIR (denileukin diftitox-cxdl), a recombinant engineered fusion protein, became commercially available in December through its subsidiary Citius Oncology (NASDAQ:CTOR).The Food and Drug Administration-approved therapy is indicated for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) who have received at least one prior systemic therapy.Leonard Mazur, Chairman and CEO of Citius Pharmaceuticals, said in the company's Tuesday press release, "This milestone reflects our ability to execute and our ...Full story available on Benzinga.com